Paul Hastings LLP advised Xencor, Inc. on the offering. Xencor, Inc. (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and...
Xencor’s $175 Million Common Stock Underwritten Public Offering
Xencor’s $100 Million Collaboration Agreement with Johnson & Johnson
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Xencor on the deal. Xencor, a clinical-stage biopharmaceutical company, announced its $100 million collaboration agreement with Johnson &...